CBI Stock Overview
A private equity and venture capital firm specializing in development stage, pre-clinical; incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Clal Biotechnology Industries Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪0.36 |
| 52 Week High | ₪0.53 |
| 52 Week Low | ₪0.29 |
| Beta | 0.73 |
| 1 Month Change | 0.56% |
| 3 Month Change | -7.77% |
| 1 Year Change | -10.55% |
| 3 Year Change | -71.72% |
| 5 Year Change | -71.10% |
| Change since IPO | -96.16% |
Recent News & Updates
Recent updates
Clal Biotechnology Industries (TLV:CBI) Is Carrying A Fair Bit Of Debt
Oct 09
The Market Doesn't Like What It Sees From Clal Biotechnology Industries Ltd.'s (TLV:CBI) Revenues Yet
Apr 18Calculating The Fair Value Of Clal Biotechnology Industries Ltd. (TLV:CBI)
Jul 14Does Clal Biotechnology Industries (TLV:CBI) Have A Healthy Balance Sheet?
Jan 19Investors Shouldn't Be Too Comfortable With Clal Biotechnology Industries' (TLV:CBI) Robust Earnings
Mar 25Clal Biotechnology Industries (TLV:CBI) Seems To Use Debt Quite Sensibly
Mar 24Introducing Clal Biotechnology Industries (TLV:CBI), The Stock That Zoomed 121% In The Last Year
Feb 16
What Kind Of Shareholders Own Clal Biotechnology Industries Ltd. (TLV:CBI)?
Jan 12Is Clal Biotechnology Industries (TLV:CBI) Using Too Much Debt?
Dec 07Shareholder Returns
| CBI | IL Biotechs | IL Market | |
|---|---|---|---|
| 7D | 1.1% | -3.4% | 0.2% |
| 1Y | -10.6% | -26.4% | 23.2% |
Return vs Industry: CBI exceeded the IL Biotechs industry which returned -26.4% over the past year.
Return vs Market: CBI underperformed the IL Market which returned 23.2% over the past year.
Price Volatility
| CBI volatility | |
|---|---|
| CBI Average Weekly Movement | 5.0% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in IL Market | 8.0% |
| 10% least volatile stocks in IL Market | 3.0% |
Stable Share Price: CBI has not had significant price volatility in the past 3 months compared to the IL market.
Volatility Over Time: CBI's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | Avi Fischer | www.cbi.co.il |
Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical; incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It prefers to invest in life sciences, medical devices, biopharmaceutical technologies, and biotechnology companies. The firm seeks to invest in companies based in United States, and Israel.
Clal Biotechnology Industries Ltd. Fundamentals Summary
| CBI fundamental statistics | |
|---|---|
| Market cap | ₪55.84m |
| Earnings (TTM) | -₪74.74m |
| Revenue (TTM) | ₪32.00k |
1,745x
P/S Ratio-0.7x
P/E RatioIs CBI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CBI income statement (TTM) | |
|---|---|
| Revenue | ₪32.00k |
| Cost of Revenue | ₪0 |
| Gross Profit | ₪32.00k |
| Other Expenses | ₪74.77m |
| Earnings | -₪74.74m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.48 |
| Gross Margin | 100.00% |
| Net Profit Margin | -233,553.13% |
| Debt/Equity Ratio | 26.2% |
How did CBI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 20:34 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Clal Biotechnology Industries Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pravin Gondhale | Virtua Research Inc. |